Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Drug Discovery Today

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2011.10.003PMID 22016087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of microsomal prostaglandin E synthase-1 in the facilitation of angiogenesis and the healing of gastric ulcers.

  2010cited by this paper
• Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol.

  2010cited by this paper
• Historical perspectives: drug interactions – it all began with cheese

  2010cited by this paper
• Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

  2009cited by this paper
• (–)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties

  2007cited by this paper
• Systems biology and combination therapy in the quest for clinical efficacy

  2006cited by this paper
• Is mPGES-1 a promising target for pain therapy?

  2006cited by this paper
• Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials.

  2005cited by this paper
• What can be learned from the experience with the fixed low-dose combination of perindopril/indapamide in the treatment of hypertension?

  2005cited by this paper
• A strategy to reduce cardiovascular disease by more than 80%

  2003cited by this paper
• Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial.

  2002cited by this paper
• The Importance of Using Scientific Principles in the Development of Medicinal Agents from Plants

  2001cited by this paper
• Combined oral contraceptives: acceptability and effective use.

  1993cited by this paper

• Determining sex differences in aortic valve myofibroblast responses to drug combinations identified using a digital medicine platform

  2025cites this paper
• Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer.

  2025cites this paper
• Activatable near-infrared fluorogenic probe for monitoring GSH variations in synergistic PTX and RSL3 treatment of hypopharyngeal carcinoma

  2025cites this paper
• Determining sex differences in drug combinations targeting aortic valve myofibroblast activation using an artificial intelligence derived platform

  2024cites this paper
• Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

  2022cites this paper
• Polypharmacology: The Science of Multi-targeting Molecules.

  2022cites this paper
• Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond.

  2022cites this paper
• Recent Advances in PROTAC Technology Toward New Therapeutic Modalities

  2022cites this paper
• Icaritin and intratumoral injection of CpG treatment synergistically promote T cell infiltration and antitumor immune response in mice.

  2022cites this paper
• Phenotypic drug discovery: recent successes, lessons learned and new directions

  2022cites this paper
• An In Silico Method for Predicting Drug Synergy Based on Multitask Learning

  2021cites this paper
• Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy.

  2021cites this paper
• Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

  2021cites this paper
• Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.

  2020cites this paper
• Discovery of talmapimod analogues as polypharmacological anti-inflammatory agents

  2019cites this paper
• Ensemble Prediction of Synergistic Drug Combinations Incorporating Biological, Chemical, Pharmacological, and Network Knowledge

  2019cites this paper
• Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.

  2019cites this paper
• Pharmacological plasticity—How do you hit a moving target?

  2019cites this paper
• Dinaciclib Inhibits Glioblastoma Multiforme Cell Growth and Selects for a Brain Tumour Initiating Cell Population

  2019cites this paper
• Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.

  2018cites this paper
• Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.

  2018cites this paper
• Computational functional genomics-based approaches in analgesic drug discovery and repurposing.

  2018cites this paper
• Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain

  2017cites this paper
• Designing Approaches to Multitarget Drugs

  2017cites this paper
• Advances in computational approaches in identifying synergistic drug combinations

  2017cites this paper
• Small molecules with anti-inflammatory properties in clinical development.

  2016cites this paper
• Process Pharmacology: A Pharmacological Data Science Approach to Drug Development and Therapy

  2016cites this paper
• Protein engineering: a new frontier for biological therapeutics.

  2015cites this paper
• Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism.

  2014cites this paper
• Inhibitors of the arachidonic acid cascade: interfering with multiple pathways.

  2014cites this paper
• Personalized Network-Based Treatments in Oncology

  2013cites this paper
• Functional genomics of pain in analgesic drug development and therapy.

  2013cites this paper
• Personalized Network‐Based Treatments in Oncology

  2013cites this paper
• Unique Risks, Benefits, and Challenges of Developing Drug-Drug Combination Products in a Pharmaceutical Industrial Setting

  2012cites this paper
• Designed multiple ligands: basic research vs clinical outcomes.

  2012cites this paper